D-1260-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1260-2020 was initiated by Teva Pharmaceuticals USA on March 5, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component. The recall status is terminated (terminated November 19, 2020). Affected quantity: 600 cartons/2 auto-injector per carton.

Recall Details

Product Type
Drugs
Report Date
May 13, 2020
Initiation Date
March 5, 2020
Termination Date
November 19, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
600 cartons/2 auto-injector per carton

Product Description

Epinephrine Injection USP, 0.3 mg (Auto-Injector), 0.3 mg/ 0.3 mL pre-filled syringe, Rx Only, Manufactured for Teva Pharmaceuticals USA, Inc. North Wales, PA 19454. NDC 0093-5986-27

Reason for Recall

CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component.

Distribution Pattern

Product was distributed to 1 wholesaler who still had all units within their possession and had not shipped or further distributed any of the product.

Code Information

Lot # 007F19AA, exp. date 04/2021